A few examples include selective inhibitors of PDE3, PDE4 and PDE5 which were the earliest drugs approved by FDA for the treatment of some cardiovascular diseases (CVDs), i.e., hypertension, thrombosis and thrombosis associated-complications and congestive heart failure (CHF), whereas inhibitors of PDE2, PDE3, PDE4 and PDE10 have been exploited for neurodevelopmental disorders [2,3]. This evidence concerns the gene PDE4A and congestive heart failure.